← Back to Encyclopedia
01 — Identity
Name & Classification
KPV is a tripeptide composed of three amino acids: Lysine–Proline–Valine. It represents the C-terminal fragment (positions 11–13) of alpha-melanocyte stimulating hormone (α-MSH), which is itself a potent endogenous anti-inflammatory neuropeptide.
KPV is classified as a melanocortin-derived anti-inflammatory peptide. Unlike its parent molecule α-MSH, KPV lacks hormonal activity but retains — and in some studies exceeds — the anti-inflammatory and antimicrobial potency of the full sequence. It acts primarily on gut epithelium, immune cells, and skin via NF-κB pathway inhibition.
Also known as: α-MSH(11-13) | H-Lys-Pro-Val-OH
02 — Origin
When It Was Developed
1980s–90s
Research into α-MSH's anti-inflammatory properties identified that its potency resided primarily in specific sequence fragments. KPV (the C-terminal tripeptide) was isolated and found to replicate key anti-inflammatory effects.
1990s–2000s
Studies by Dr. Anna Catania and others demonstrated KPV's ability to suppress fever, reduce local and systemic inflammation, and inhibit NF-κB signaling without the pigmentation effects of full α-MSH.
2000s–2010s
Growing body of research on gut health applications — KPV shown to reduce intestinal inflammation in IBD models, improve mucosal barrier integrity, and suppress pro-inflammatory cytokine production in colonic tissue.
2015–Present
Increasing use in functional medicine for IBD, leaky gut, skin conditions, and systemic inflammation. Both injectable and oral/topical routes studied. No FDA approval; research peptide status.
03 — Research History
Research Background
KPV was identified through systematic research on which portion of α-MSH was responsible for its powerful anti-inflammatory effects. The tripeptide was found to be the minimal active sequence — capable of inhibiting NF-κB, reducing pro-inflammatory cytokines (TNF-α, IL-6, IL-1β), and suppressing fever in animal models at doses comparable to full-length α-MSH.
Particularly compelling is its role in gut health. Research showed KPV can be taken orally and survives intestinal transit well enough to act locally on colonic mucosa — a major advantage over injectable peptides for gut conditions. Studies in colitis models showed KPV reduced inflammation scores, preserved crypt architecture, and improved barrier function by upregulating tight junction proteins.
KPV also shows direct antimicrobial activity against several pathogens including Candida albicans and Staphylococcus aureus, suggesting a dual role as both anti-inflammatory and antimicrobial agent in mucosal tissues.
04 — Key Benefits
Proposed Benefits
Potent NF-κB inhibition — master inflammation switch
Reduces TNF-α, IL-6, IL-1β in gut and systemic tissue
Heals intestinal mucosal barrier — tight junction upregulation
Effective in IBD/colitis models (Crohn's, UC)
Oral route viable — survives gut transit to act locally
Antimicrobial activity against Candida and Staph aureus
Skin anti-inflammatory — effective topically for dermatitis
No hormonal activity — no pigmentation or endocrine effects
05 — Reconstitution
10 mg Vial + 300 Units BAC Water
33.3 mcg
per unit drawn on insulin syringe
4–6 wk
shelf life (fridge)
🧊
RECONSTITUTED SHELF LIFE
30 days after mixing
Tripeptide, relatively stable. 30-day window.
Storage: 2–8°C (fridge) · Protected from light · Do NOT freeze
Preload syringes/cartridges to minimize vial disturbance
KPV is also available in oral capsule form (typically 500 mcg–2 mg per capsule) for targeted gut action. Injectable form reconstituted with BAC water as above. For gut-focused protocols, oral is preferred; for systemic or skin applications, subcutaneous injection or topical is used. Store refrigerated at 36–46°F / 2–8°C.
06 — Dosage
Dosage Reference
🎯 PICK YOUR PROTOCOL · DOSING DIFFERS BY GOAL
🌱
GUT / IBD
For intestinal inflammation, leaky gut, IBD-like symptoms. Local action on colonic mucosa.
ROUTE
Oral capsules
DOSE
500 mcg – 2 mg / day
WHY ORAL
Survives intestinal transit · acts locally on colonic epithelium · skips first-pass metabolism advantage isn't needed when target IS the gut.
💉
SYSTEMIC
For systemic inflammation, joint inflammation, skin conditions, recovery support.
ROUTE
Subcutaneous injection
DOSE
500 mcg – 1 mg / day
WHY SC
Direct systemic circulation · acts on immune cells, joints, skin · daily injection · 15-30u on a 100u pen.
🔄 Can be combined: Oral KPV (gut) + SC KPV (systemic) is a valid protocol for users with both gut + systemic inflammation. Use different doses for each route.
| Dose | Units / Format | Context |
|---|
| 100–250 mcg SC | 3–7.5 u | LOW / INTRO · SC |
| 500 mcg SC | 15 u | COMMON · SC |
| 500 mcg–2 mg oral | 1–4 capsules | GUT · ORAL |
| 1–2 mg SC | 30–60 u | STANDARD · SC |
07 — Monitoring
Biomarkers, Lab Tests & Ranges
KPV targets intestinal inflammation, systemic inflammatory cytokines, and gut barrier integrity. Monitor these markers before, at 6 weeks, and at cycle end.
▸ Gut Barrier & Intestinal Health
| Biomarker | Lab Test | Clinical Range | Optimal Range |
|---|
Zonulin
Intestinal permeability marker | Serum or Stool Zonulin | CLINICAL<107 ng/mL (serum) | OPTIMAL<40 ng/mL |
LPS (Lipopolysaccharide)
Bacterial translocation marker | Serum LPS / LPS-binding protein | CLINICALLBP <7.5 µg/mL | OPTIMALLBP <5.0 µg/mL |
Calprotectin
Gut inflammation marker | Stool Calprotectin | CLINICAL<50 µg/g | OPTIMAL<25 µg/g |
| Secretory IgA (sIgA) | Stool sIgA | CLINICAL510–2040 µg/g | OPTIMAL700–1500 µg/g |
▸ Systemic Inflammation
| Biomarker | Lab Test | Clinical Range | Optimal Range |
|---|
| hsCRP | High-sensitivity CRP | CLINICAL<3.0 mg/L | OPTIMAL<0.5 mg/L |
| IL-6 | Serum Interleukin-6 | CLINICAL<7.0 pg/mL | OPTIMAL<1.5 pg/mL |
| TNF-α | Serum TNF-alpha | CLINICAL<8.1 pg/mL | OPTIMAL<2.0 pg/mL |
| ESR | Erythrocyte Sedimentation Rate | CLINICAL0–22 (M) / 0–29 (F) mm/hr | OPTIMAL<10 mm/hr |
▸ Safety
| Biomarker | Lab Test | Clinical Range | Optimal Range |
|---|
| AST / ALT | CMP | CLINICALAST 10–40 / ALT 7–56 U/L | OPTIMALAST <26 / ALT <26 U/L |
| CBC | Complete Blood Count | CLINICALStandard ranges | OPTIMALMid-range; WBC 4.5–6.0 |
READY TO ADD THIS TO YOUR STACK?
Drop KPV into your protocol tracker — dosing pre-filled, timing set, cycle ready.
ADD TO MY PROTOCOL →
Saves your dose selection. Returns you here after.
⚠ KPV is not FDA-approved. It is derived from an endogenous sequence (α-MSH) and has a strong safety profile in research. Stool testing (calprotectin, zonulin, sIgA) is particularly valuable for tracking gut-focused protocols. Consult a qualified practitioner.
08 — Cycle Protocol
Cycle Length, Frequency & Timing
▸ How Long to Cycle
RESEARCH PROTOCOLS
8–12 Weeks
Animal IBD and colitis studies used 4–12 week treatment courses. Functional improvements in gut histology visible from week 4.
PRACTITIONER CONSENSUS
12–16 Weeks
Gut healing typically requires sustained support. Most practitioners run 12–16 week cycles for IBD/leaky gut, with off-period biomarker reassessment before re-cycling.
KPV has one of the most favorable safety profiles of any research peptide given its endogenous origin. Longer cycles are considered acceptable. For chronic gut conditions, some practitioners use intermittent longer protocols with periodic breaks every 16–20 weeks.
▸ Frequency & Timing
| Variable | Recommendation | Why |
|---|
| Frequency (injectable) | Daily (7×/week) | Daily dosing maintains consistent NF-κB suppression. KPV's short half-life means consistent daily administration is needed for systemic effect. |
| Frequency (oral) | 1–2× daily with food | Oral dosing with meals delivers KPV to intestinal epithelium during digestion — maximizing local gut contact time. Split AM/PM dosing for twice-daily regimens. |
| Fasted vs Fed (injectable) | ~ Either acceptable | Unlike metabolic peptides, KPV does not require a fasted state. Its anti-inflammatory mechanism is not insulin-sensitive. AM fasted is conventional; no strong data for preference. |
| Fasted vs Fed (oral) | ✓ With food | Taking oral KPV with food extends gut contact time and maximizes local anti-inflammatory effect on intestinal mucosa. The transit time through the gut is the delivery window. |
| Timing | AM preferred | Morning dosing aligns with peak inflammatory cytokine production (which is typically highest in the early morning). May be most effective when administered before the daily inflammatory peak. |
⚖️ NOT SURE IF THIS IS THE RIGHT PEPTIDE?
Put this peptide head-to-head with similar compounds. See ratings, costs, stacking conflicts — pick the right one for your goal.
Compare Peptides →